Xeris Pharmaceuticals

Performance

About Xeris Pharmaceuticals

Xeris Pharmaceuticals is a growth-oriented biopharmaceutical company focused on developing and commercializing advanced, ready-to-use therapeutic medicines across a range of endocrine and metabolic disorders. The company operates primarily in the United States, with a portfolio of approved injectable and stable-formulation products and an ongoing pipeline leveraging proprietary formulation technologies. Its marketed products include Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for endogenous hypercortisolemia, among others, signaling a specialty in ready-to-use solutions that simplify patient treatment. Xeris emphasizes patient impact, innovation, and partnerships to extend product use across diverse therapeutic areas.